Nicholas J Holman is a notable inventor based in Leominster, MA (US). He holds a total of 8 patents, showcasing his significant contributions to the field of immunoconjugates. His work primarily focuses on improving methods and compositions for preparing SN-38 conjugates, which are crucial in the treatment of various diseases.

Latest Patents

One of Holman's latest patents involves Antibody-SN-38 immunoconjugates with a CL2A linker. This invention concerns improved methods for preparing SN-38 conjugates of proteins or peptides, particularly immunoconjugates of antibodies or antigen-binding antibody fragments. The SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with a range of 1-12, preferably 6-8, or alternatively 1-5 SN-38 moieties per antibody or antibody fragment. The immunoconjugate is designed to be prepared in large-scale batches, with modifications to the reaction scheme to optimize yield and recovery. Additionally, the patent addresses optimized dosages and schedules of administration to maximize efficacy while minimizing side effects.

Career Highlights

Throughout his career, Holman has worked with prominent companies in the field, including Immunomedics, Inc. and Immunimedics, Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions in immunotherapy.

Collaborations

Some of Holman's notable coworkers include Serengulam V Govindan and Jonathan B Gale. Their collaborative efforts have likely played a role in advancing the research and development of immunoconjugates.

Conclusion

Nicholas J Holman is a distinguished inventor whose work in immunoconjugates has the potential to significantly impact disease treatment. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.